RinLis® (insulin lispro)

Widely used fast acting insulin analogue
Characterised by reverse lysine and priline residues on amino acid sequence in the insulin amino acid chain
Fast absorption from subcutaneous injections sites
Onset of action after subcutaneous administrationin -15 min
Maximum action - in 0.5–2.5 hours
Duration of action 3–4 hours

Pharmacokinetic properties

The pharmacokinetics of insulin lispro reflect a compound that is rapidly absorbed, and achieves peak blood levels 30 to 70 minutes following subcutaneous injection. When considering the clinical relevance of these kinetics, it is more appropriate to examine the glucose utilization curves/

Renal impairment

Insulin lispro maintains more rapid absorption when compared to soluble human insulin in patients with renal impairment. In patients with type 2 diabetes over a wide range of renal function the pharmacokinetic differences between insulin lispro and soluble human insulin were generally maintained and shown to be independent of renal function.

Hepatic impairment

Insulin lispro maintains more rapid absorption and elimination when compared to soluble human insulin in patients with hepatic impairment.